19,736 Insmed, Inc. $INSM Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp lessened its position in Insmed, Inc. (NASDAQ:INSM – Free Report) by 43.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,108 shares of the biopharmaceutical company’s stock after selling 19,736 shares during the period. Fifth Third Bancorp’s holdings in Insmed were worth $2,980,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in INSM. Bank of New York Mellon Corp purchased a new stake in shares of Insmed in the second quarter worth $139,966,000. Assenagon Asset Management S.A. boosted its stake in shares of Insmed by 480.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock valued at $144,591,000 after purchasing an additional 1,048,518 shares during the period. Railway Pension Investments Ltd bought a new position in Insmed in the second quarter worth approximately $64,473,000. Pictet Asset Management Holding SA increased its stake in shares of Insmed by 44.0% during the third quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company’s stock valued at $200,845,000 after buying an additional 537,188 shares during the period. Finally, Sei Investments Co. raised its holdings in shares of Insmed by 56.8% in the first quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after acquiring an additional 505,624 shares in the last quarter.

Insmed Price Performance

Shares of INSM opened at $144.46 on Friday. The company’s fifty day moving average price is $110.85 and its 200-day moving average price is $122.79. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.86 and a quick ratio of 2.59. The firm has a market capitalization of $31.69 billion, a PE ratio of -51.23 and a beta of 0.83. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The business had revenue of $524.43 million during the quarter, compared to analyst estimates of $500.36 million. During the same quarter last year, the company posted ($1.75) EPS. Insmed’s quarterly revenue was up 268.4% compared to the same quarter last year. On average, equities research analysts predict that Insmed, Inc. will post -1.86 EPS for the current year.

Insider Activity

In other news, Director David Brennan sold 25,000 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the transaction, the director owned 39,238 shares of the company’s stock, valued at $4,865,512. The trade was a 38.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on INSM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research report on Thursday, October 15th. Bank of America reaffirmed a “buy” rating and set a $207.00 target price on shares of Insmed in a research report on Monday, October 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $235.00 target price on shares of Insmed in a report on Tuesday, July 28th. Barclays decreased their price target on shares of Insmed from $237.00 to $207.00 and set an “overweight” rating for the company in a research report on Wednesday, September 30th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $196.52.

View Our Latest Analysis on INSM

Key Headlines Impacting Insmed

These are some of the INSM headlines that stood out recently:

  • Positive Sentiment: Reports that Sanofi is considering buying Insmed prompted investors to price in the possibility of a takeover premium. Bloomberg Law article
  • Positive Sentiment: An analyst cited in coverage suggested Insmed could be worth $170–$210 per share in a takeover, adding to investor expectations for a premium. Seeking Alpha article
  • Neutral Sentiment: Trading activity was unusually elevated, including increased call-option purchases, while a brief LULD pause reflected sharp volatility. These signals show heightened interest but do not confirm a transaction. Proactive Investors article

Insmed Profile

(Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Read More

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.